#ASCO23 Tweetorial on putting results of PEACE-1 in context. Here we go!

@ASCO @ASTRO_org @HimanshuNagarMD @DrRanaMcKay @AlbertoBossial @Prof_Nick_James @PCaParker 1/n

ADT + tx intensification w/ chemo or ARSI is SOC based on lots of RCTs

No OS diff seen in STAMPEDE from ADT+Abi vs ADT+doce (FFS difference as ARSI suppress PSA = FFS).

No clear role of triplet therapy in low volume (ARASENS)

Thus, SOC is ADT+doce or ARSI for low volume

While I respect Dr. Ehdaie greatly, I must call it like it is given the high profile nature of Lancet Oncology.

Here would be roughly my response to the numerous fallacies and what reads as a spin job in order to push HIFU:

@NicholasZaorsky @AmarUKishan @HimanshuNagarMD

https://twitter.com/BehfarEhdaieMD/status/1600532828344979457

Fallacy #1:
Dr. Ehdaie et al begin their reply by stating it is invalid to compare outcomes from pts treated 20-30 yrs ago.
Yet they cited data on positive post tx bx from data 30-40 years ago with low dose 2D and 3D RT.

@seanmmcbride @DrAndrewLoblaw @aleberlin2 @RonaldChenMD

@ParikhSimul @SprakerMDPhD Been absent on SDN and twitter mostly lately. Thanks for the good read. Here is my thoughts on COI as I have evolved over time and struggle given I have seen 1st hand when COIs cloud judgement. I also have seen those without expertise make incorrect interpretations.
Here we go... @ParikhSimul @SprakerMDPhD 1/n I started my career declining all COIs. Was taught from med school they make you biased & pharma/industry were evil. I felt like I was pure & proud to have no COIs. Then I got to know people who worked for industry and those who transitioned from academics to industry...

@aj2279 @NicholasZaorsky and myself wrote a quick commentary to @TheLancet for the @NRGonc RTOG 0534/SPPORT trial. Didnt make the cut so figured I would just post here if of interest to anyone.

Their word limit is crazy short.

1/n
Too much noise, I figured it has been awhile since I did a tweetorial. Here you go for SSPORT/RTOG 0534

@NRGonc @ASTRO_org @ARRO_org @QuadShotNews 2/n

1st read up on the 1st RCT of SRT +/- hormone therapy (HT), RTOG 9601, and why men getting early SRT at low pre-SRT PSAs should NOT get ADT: jamanetwork.com/journals/jamao…

@rtdess @AarmstrongDuke

1/n I write this without knowing where to start, but what I know is I have a voice and that voice may reach people where other voices may not, or at least reinforce the voices of others.
After reading, listening, talking with those effected, here is what I know and what I dont 2/n Staying quiet, respectful, and polite is not enough. I need to actively be anti-racist. I need to actively be willing to relinquish power, and encourage others to as well to accelerate equality in America. Although some of that power was earned, much was also born into

1/
TWEETORIAL of GETUG-16 and hormone therapy with SRT

I have been asked many times to discuss this paper and my views on the topic now that the GETUG-16 was updated. It is a great trial with numerous strengths. So here we go…
@MCWardMD @RTendulkarMD @subatomicdoc #PCSM @MCWardMD @RTendulkarMD @subatomicdoc 2/
Overall the trial can be viewed as positive or negative. How is this?

Original primary endpoint: PFS = was met!

Sample size was increased to be powered for OS, which was not met. So the endpoint the trial was actually powered for was not met = negative.